Welcome to our dedicated page for Adagio Medical Holdings SEC filings (Ticker: ADGM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Adagio Medical Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Adagio Medical Holdings's regulatory disclosures and financial reporting.
ADAR1 Capital Management, LLC and Daniel Schneeberger report beneficial ownership of Adagio Medical Holdings, Inc. common stock. They disclose shared voting and dispositive power over 1,205,447 shares of common stock, representing 5.4% of the class, based on 22,210,459 shares outstanding as of June 30, 2026.
The reported stake consists of 1,054,697 shares held by ADAR1 Partners, LP and 150,750 shares held by Spearhead Insurance Solutions IDF, LLC. Additional potential equity exposure is excluded from this figure: 1,733,980 shares underlying milestone warrants and 500,000 shares issuable upon conversion of 13% senior secured convertible notes held by ADAR1 Partners, LP, plus 185,138 shares underlying milestone warrants held by Spearhead Insurance Solutions IDF, LLC, all subject to a 4.99% beneficial ownership limitation.
Adagio Medical Holdings, Inc. reported that on August 13, 2026 it received a Nasdaq deficiency letter for failing to meet the Nasdaq Capital Market minimum stockholders’ equity requirement. Nasdaq Listing Rule 5550(b)(1) requires at least $2,500,000 of stockholders’ equity, while the company’s Form 10-Q for the quarter ended June 30, 2026 reported stockholders’ equity of $(415,000). The company also does not meet the alternative standards based on market value of listed securities or net income from continuing operations. The notice has no immediate effect on the Nasdaq listing. Adagio has 45 days, no later than September 28, 2026, to submit a compliance plan; if accepted, Nasdaq may grant up to 180 additional days to regain compliance. The company plans to submit the compliance plan, monitor equity and evaluate options, while highlighting risks around liquidity, financing needs and its ability to continue operating as a going concern.
Adagio Medical Holdings, Inc. made available an updated corporate presentation on August 13, 2026 for use in meetings with investors, analysts and other stakeholders. The presentation is accessible on the company’s website and is also included as Exhibit 99.1.
The information in this investor presentation, as described under the company’s Regulation FD disclosure, is being furnished rather than filed under the Exchange Act and is not incorporated by reference into other Securities Act or Exchange Act reports.
Adagio Medical Holdings, Inc. director Sean Salmon received a grant of 30,000 non-qualified stock options to buy common stock. The options have an exercise price of $0.7103 per share, expire on June 16, 2036, and will vest in 12 equal monthly installments over one year starting June 16, 2026.
Adagio Medical Holdings, Inc. reported that director Keyvan Mirsaeedi-Farahani received a grant of 30,000 non-qualified stock options on June 16, 2026. The options have an exercise price of $0.7103 per share and expire on June 16, 2036. They were granted under the company’s Non-Employee Director Compensation Policy and 2024 Equity Incentive Plan and will vest in 12 equal monthly installments over one year starting from the vesting commencement date of June 16, 2026. After this grant, the reporting person holds 30,000 options directly.
Adagio Medical Holdings, Inc. reported that director James L. Cox received a grant of a non-qualified stock option for 30,000 shares of common stock on June 16, 2026. The option has an exercise price of $0.7103 per share and expires on June 16, 2036. It vests in equal monthly installments over one year, with 1/12 of the shares vesting after each month of continuous service beginning on the vesting commencement date of June 16, 2026. Following this grant, Cox holds 30,000 option shares directly.
Adagio Medical Holdings, Inc. reported that director Sandra A. Gardiner received a grant of 30,000 non-qualified stock options on June 16, 2026 under the Non-Employee Director Compensation Policy and 2024 Equity Incentive Plan. The options have an exercise price of $0.7103 per share and expire on June 16, 2036. They vest in equal monthly installments over one year, with 1/12 of the underlying shares vesting at the end of each month of continuous service after the June 16, 2026 vesting commencement date, resulting in 30,000 options held directly after this grant.
Adagio Medical Holdings, Inc. director Orly Mishan received a grant of 100,000 non-qualified stock options on June 16, 2026 under the company’s Non-Employee Director Compensation Policy and 2024 Equity Incentive Plan. The options have an exercise price of $0.7103 per share and expire on June 16, 2036. They vest in equal monthly installments over one year, with 1/12 of the underlying shares vesting after each month of continuous service following the vesting commencement date of June 16, 2026.
Adagio Medical Holdings, Inc. reported that director Timothy P. Moran received a grant of 30,000 non-qualified stock options on 2026-06-16. The options have an exercise price of $0.7103 per share and expire on 2036-06-16.
The grant was made under the company’s Non-Employee Director Compensation Policy and 2024 Equity Incentive Plan. The option will vest in equal monthly installments over one year, with 1/12 of the underlying shares vesting at the conclusion of each month of continuous service after the vesting commencement date of 06/16/2026. Following this grant, Moran holds 30,000 derivative securities directly.
Adagio Medical Holdings, Inc., a cardiac ablation technology company, reported continued operating losses and tight liquidity for the quarter ended June 30, 2026. Cash and cash equivalents were $7.7 million, down from $17.1 million at December 31, 2025, while total assets declined to $33.9 million. Convertible notes payable measured at fair value increased to $24.8 million, and total liabilities of $34.3 million exceeded assets, resulting in stockholders’ deficit equity of $(0.4) million.
The company generated no revenue in the three and six months ended June 30, 2026 and 2025. Net loss was $6.7 million for the quarter (vs. $3.9 million a year earlier) and $13.7 million for the first six months of 2026 (vs. $11.7 million in 2025). Net cash used in operating activities for the six-month period was $9.4 million, following $11.9 million used in the prior-year period.
The company highlights development of its vCLAS Ventricular Ablation Systems based on its Ultra-Low Temperature Ablation platform. It submitted a Premarket Approval application to the FDA in May 2026 after completing enrollment and six‑month pivotal results in its U.S. IDE trial, and holds FDA Breakthrough Device designation and a European CE Mark for the vCLAS system. Management discloses substantial doubt about the company’s ability to continue as a going concern within one year, noting current cash is expected to fund operations only into the fourth quarter of 2026 and that additional equity, debt or strategic financing and cost reductions are planned but not assured.